---
layout: default
title: Regorafenib
description: "Regorafenib çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚é«˜è­‰æ“šç­‰ç´š L2ï¼ŒåŒ…å« 8 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 145
evidence_level: L2
indication_count: 8
---

# Regorafenib

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L2</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>8</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Regorafenibï¼šå¾å¤§è…¸ç›´è…¸ç™Œåˆ°è„‚è‚ªè‚‰ç˜¤

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Regorafenib å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Regorafenib æ˜¯ä¸€ç¨®å¤šæ¨™é¶æ¿€é…¶æŠ‘åˆ¶åŠ‘ï¼ŒåŸæœ¬ç”¨æ–¼è½‰ç§»æ€§å¤§è…¸ç›´è…¸ç™Œã€èƒƒè…¸é“é–“è³ªè…«ç˜¤ï¼ˆGISTï¼‰å’Œè‚ç´°èƒç™Œçš„æ²»ç™‚ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**è„‚è‚ªè‚‰ç˜¤ (Liposarcoma)** æœ‰æ•ˆï¼Œç›®å‰æœ‰ **2 å€‹è‡¨åºŠè©¦é©—**å’Œ **9 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | è½‰ç§»æ€§å¤§è…¸ç›´è…¸ç™Œã€èƒƒè…¸é“é–“è³ªè…«ç˜¤ã€è‚ç´°èƒç™Œ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | liposarcomaã€ovarian myxoid liposarcomaã€clear cell renal carcinomaã€unclassified renal cell carcinomaã€renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusionsã€renal cell carcinoma associated with neuroblastomaã€childhood kidney cell carcinomaã€vulva sarcoma |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.76% |
| è­‰æ“šç­‰ç´š | L2 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 1 å¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |





## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. liposarcoma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.76%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>Regorafenib æ˜¯ä¸€ç¨®å£æœå¤šæ¨™é¶æ¿€é…¶æŠ‘åˆ¶åŠ‘ï¼Œå¯æŠ‘åˆ¶å¤šç¨®åƒèˆ‡è…«ç˜¤è¡€ç®¡æ–°ç”Ÿã€è…«ç˜¤å¾®ç’°å¢ƒå’Œè…«ç˜¤å¢æ®–çš„æ¿€é…¶ï¼ŒåŒ…æ‹¬ï¼š</p>
<ul>
<li>VEGFR1-3ï¼ˆè¡€ç®¡æ–°ç”Ÿï¼‰</li>
<li>TIE2ï¼ˆè¡€ç®¡æ–°ç”Ÿï¼‰</li>
<li>PDGFR-Î²ï¼ˆè…«ç˜¤å¾®ç’°å¢ƒï¼‰</li>
<li>FGFRï¼ˆçº–ç¶­æ¯ç´°èƒç”Ÿé•·å› å­å—é«”ï¼‰</li>
<li>KITã€RETã€RAFï¼ˆè…«ç˜¤å¢æ®–ï¼‰</li>

</ul>
<p>è„‚è‚ªè‚‰ç˜¤æ˜¯ä¸€ç¨®æºè‡ªè„‚è‚ªçµ„ç¹”çš„æƒ¡æ€§è…«ç˜¤ï¼Œå±¬æ–¼è»Ÿçµ„ç¹”è‚‰ç˜¤ã€‚èˆ‡å¤§è…¸ç›´è…¸ç™Œå’Œ GIST é¡ä¼¼ï¼Œè„‚è‚ªè‚‰ç˜¤çš„ç”Ÿé•·å’Œè½‰ç§»ä¹Ÿä¾è³´è¡€ç®¡æ–°ç”Ÿå’Œç‰¹å®šçš„ä¿¡è™Ÿå‚³å°é€”å¾‘ã€‚</p>

<p>Regorafenib çš„å¤šæ¨™é¶ç‰¹æ€§ä½¿å…¶åœ¨æŠ‘åˆ¶è…«ç˜¤è¡€ç®¡æ–°ç”Ÿå’Œè…«ç˜¤å¾®ç’°å¢ƒæ–¹é¢å…·æœ‰æ½›åœ¨å„ªå‹¢ã€‚å·²æœ‰å¤šé …è‡¨åºŠè©¦é©—ï¼ˆåŒ…æ‹¬ SARC024 å’Œ REGOSARCï¼‰æ¢è¨ regorafenib åœ¨è»Ÿçµ„ç¹”è‚‰ç˜¤ä¸­çš„ç™‚æ•ˆã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02048371" target="_blank">NCT02048371</a></td><td>PHASE2</td><td>COMPLETED</td><td>131</td><td>SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01900743" target="_blank">NCT01900743</a></td><td>PHASE2</td><td>COMPLETED</td><td>219</td><td>Activity and Safety of Regorafenib in Patients With Metastatic Soft Tissue Sarco...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29902612/" target="_blank">29902612</a></td><td>2018</td><td>Article</td><td>European journal of cancer (Ox</td><td>Efficacy and safety of regorafenib compared to placebo and to post-cross-over re...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33290314/" target="_blank">33290314</a></td><td>2021</td><td>Article</td><td>Anti-cancer drugs</td><td>Efficacy and safety of anlotinib in patients with unresectable or metastatic wel...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29931504/" target="_blank">29931504</a></td><td>2018</td><td>Article</td><td>Targeted oncology</td><td>Growing Role of Regorafenib in the Treatment of Patients with Sarcoma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27751846/" target="_blank">27751846</a></td><td>2016</td><td>Article</td><td>The Lancet. Oncology</td><td>Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40975452/" target="_blank">40975452</a></td><td>2025</td><td>Article</td><td>Critical reviews in oncology/h</td><td>Maintenance after first-line treatment for advanced soft tissue sarcoma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32701199/" target="_blank">32701199</a></td><td>2020</td><td>Article</td><td>The oncologist</td><td>A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Ve...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25884155/" target="_blank">25884155</a></td><td>2015</td><td>Article</td><td>BMC cancer</td><td>Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28295221/" target="_blank">28295221</a></td><td>2017</td><td>Article</td><td>Cancer</td><td>REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarco...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26266019/" target="_blank">26266019</a></td><td>2015</td><td>Article</td><td>Rare tumors</td><td>Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. ovarian myxoid liposarcoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.68%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. clear cell renal carcinoma</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.47%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ1 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03475953" target="_blank">NCT03475953</a></td><td>PHASE1, PHASE2</td><td>UNKNOWN</td><td>747</td><td>A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24756792/" target="_blank">24756792</a></td><td>2014</td><td>Article</td><td>Recent results in cancer resea</td><td>Regorafenib.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30069758/" target="_blank">30069758</a></td><td>2018</td><td>Article</td><td>Recent results in cancer resea</td><td>Regorafenib.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24308791/" target="_blank">24308791</a></td><td>2014</td><td>Article</td><td>Expert review of clinical phar</td><td>Novel tyrosine kinase inhibitors for renal cell carcinoma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24387233/" target="_blank">24387233</a></td><td>2014</td><td>Article</td><td>Expert opinion on investigatio</td><td>Fibroblast growth factor receptors as therapeutic targets in clear-cell renal ce...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24309512/" target="_blank">24309512</a></td><td>2014</td><td>Article</td><td>Cancer biology &amp; therapy</td><td>Multi-kinase inhibition in ovarian cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23334510/" target="_blank">23334510</a></td><td>2013</td><td>Article</td><td>Current oncology reports</td><td>Regorafenib (BAY 73-4506): stromal and oncogenic multikinase inhibitor with pote...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30304963/" target="_blank">30304963</a></td><td>2018</td><td>Article</td><td>Expert review of anticancer th</td><td>Nivolumab for the treatment of hepatocellular carcinoma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22959186/" target="_blank">22959186</a></td><td>2012</td><td>Article</td><td>The Lancet. Oncology</td><td>Regorafenib for patients with previously untreated metastatic or unresectable re...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/41324163/" target="_blank">41324163</a></td><td>2026</td><td>Article</td><td>The Korean journal of physiolo</td><td>Drug repositioning of regorafenib for renal cell carcinoma identifies DDR2â€‘assoc...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38761350/" target="_blank">38761350</a></td><td>2024</td><td>Article</td><td>Targeted oncology</td><td>Anti-Angiogenic Tyrosine Kinase Inhibitor-Related Toxicities Among Cancer Patien...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27581086/" target="_blank">27581086</a></td><td>2016</td><td>Article</td><td>Biochimica et biophysica acta</td><td>The interaction of sorafenib and regorafenib with membranes is modulated by thei...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29956623/" target="_blank">29956623</a></td><td>2018</td><td>Article</td><td>Current drug metabolism</td><td>Genetic Polymorphism on the Pharmacokinetics and Pharmacodynamics of Platelet-de...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33419029/" target="_blank">33419029</a></td><td>2021</td><td>Article</td><td>International journal of molec</td><td>Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immun...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28703624/" target="_blank">28703624</a></td><td>2017</td><td>Article</td><td>Future oncology (London, Engla</td><td>Cabozantinib in the treatment of hepatocellular carcinoma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23700287/" target="_blank">23700287</a></td><td>2013</td><td>Article</td><td>Investigational new drugs</td><td>Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23981115/" target="_blank">23981115</a></td><td>2014</td><td>Article</td><td>British journal of clinical ph</td><td>Incidence and relative risk of hepatic toxicity in patients treated with anti-an...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28166200/" target="_blank">28166200</a></td><td>2017</td><td>Article</td><td>Oncogene</td><td>Upregulation of MARCKS in kidney cancer and its potential as a therapeutic targe...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36583425/" target="_blank">36583425</a></td><td>2023</td><td>Article</td><td>Journal of the American Heart </td><td>Treatment and Implications of Vascular Endothelial Growth Factor Inhibitor-Induc...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22959187/" target="_blank">22959187</a></td><td>2012</td><td>Article</td><td>The Lancet. Oncology</td><td>Choosing the right option for renal-cell carcinoma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33436042/" target="_blank">33436042</a></td><td>2021</td><td>Article</td><td>Journal of hematology &amp; oncolo</td><td>The integration of immune checkpoint inhibitors with VEGF targeted agents in adv...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. unclassified renal cell carcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.24%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.24%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. renal cell carcinoma associated with neuroblastoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.24%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. childhood kidney cell carcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.07%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. vulva sarcoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.06%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬XXXXXXè™Ÿ | ç™Œç‘æ ¼è†œè¡£éŒ 40æ¯«å…‹ | è†œè¡£éŒ  | å¤§è…¸ç›´è…¸ç™Œã€èƒƒè…¸é“é–“è³ªè…«ç˜¤ã€è‚ç´°èƒç™Œ |

## ç´°èƒæ¯’æ€§

| é …ç›® | å…§å®¹ |
|------|------|
| ç´°èƒæ¯’æ€§åˆ†é¡ | æ¨™é¶è—¥ç‰©ï¼ˆå¤šæ¨™é¶æ¿€é…¶æŠ‘åˆ¶åŠ‘ï¼‰ |
| éª¨é«“æŠ‘åˆ¶é¢¨éšª | ä½è‡³ä¸­åº¦ï¼ˆå¯èƒ½å‡ºç¾è¡€å°æ¿æ¸›å°‘ï¼‰ |
| è‡´åæ€§åˆ†ç´š | ä½åº¦ |
| ç›£æ¸¬é …ç›® | CBCã€è‚åŠŸèƒ½ï¼ˆALT/AST/Bilirubinï¼‰ã€è¡€å£“ã€çš®è†šåæ‡‰ |
| è™•ç½®é˜²è­· | å£æœè—¥ç‰©ï¼Œéµå¾ªä¸€èˆ¬è—¥ç‰©è™•ç½®è¦ç¯„å³å¯ |

## å®‰å…¨æ€§è€ƒé‡

**ä¸»è¦è­¦èªï¼š**
- è‚æ¯’æ€§ï¼šå¯èƒ½å‡ºç¾åš´é‡è‚æå‚·ï¼Œéœ€å®šæœŸç›£æ¸¬è‚åŠŸèƒ½
- æ‰‹è¶³çš®è†šåæ‡‰ï¼ˆHFSRï¼‰ï¼šå¸¸è¦‹ä¸è‰¯åæ‡‰
- é«˜è¡€å£“ï¼šéœ€ç›£æ¸¬è¡€å£“

**ç¦å¿Œç—‡ï¼š**
è«‹åƒè€ƒåŸå» ä»¿å–®




### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**high-fat foods** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šå½±éŸ¿è—¥ç‰©å¸æ”¶ã€‚å¯èƒ½å¢å¼·è—¥æ•ˆã€‚
- å»ºè­°ï¼šå»ºè­°é¿å…ä½µç”¨ã€‚

**è‘¡è„æŸšæ±** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šå¯èƒ½å¢å¼·è—¥æ•ˆã€‚
- å»ºè­°ï¼šå»ºè­°é¿å…ä½µç”¨ã€‚é¿å…é£Ÿç”¨è‘¡è„æŸšæˆ–è‘¡è„æŸšæ±ã€‚

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**è–ç´„ç¿°è‰ï¼ˆè²«è‘‰é€£ç¿¹ï¼‰** ğŸ”´ Major
- å½±éŸ¿ï¼šè–ç´„ç¿°è‰é™ä½æ¨™é¶è—¥ç‰©ç™‚æ•ˆ
- å»ºè­°ï¼šç¦æ­¢ä½µç”¨


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Lung Diseases** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
é›–ç„¶ SARC024 å’Œ REGOSARC è©¦é©—å·²æ¢è¨ regorafenib ç”¨æ–¼è„‚è‚ªè‚‰ç˜¤ï¼Œä½†çµæœé¡¯ç¤ºåœ¨è„‚è‚ªè‚‰ç˜¤äºçµ„ä¸­ç™‚æ•ˆæœ‰é™ã€‚é€™èˆ‡å…¶ä»–è»Ÿçµ„ç¹”è‚‰ç˜¤äºå‹ï¼ˆå¦‚å¹³æ»‘è‚Œè‚‰ç˜¤ã€æ»‘è†œè‚‰ç˜¤ï¼‰çš„æ­£é¢çµæœå½¢æˆå°æ¯”ã€‚ç„¶è€Œï¼Œç”±æ–¼ä»æœ‰éƒ¨åˆ†æ‚£è€…å¯èƒ½ç²ç›Šï¼Œä¸”ç¼ºä¹å…¶ä»–æœ‰æ•ˆæ²»ç™‚é¸æ“‡ï¼Œåœ¨å……åˆ†çŸ¥æƒ…åŒæ„ä¸‹å¯è€ƒæ…®ä½¿ç”¨ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- æ ¹æ“š SARC024 å’Œ REGOSARC è©¦é©—çµæœï¼Œè¬¹æ…è©•ä¼°æ‚£è€…æ˜¯å¦é©åˆ
- å¯†åˆ‡ç›£æ¸¬è‚åŠŸèƒ½å’Œçš®è†šåæ‡‰
- æ¢ç´¢èˆ‡å…¶ä»–ç™‚æ³•ï¼ˆå¦‚å…ç–«æ²»ç™‚ï¼‰çš„çµ„åˆæ–¹æ¡ˆ
- è€ƒæ…®ç”Ÿç‰©æ¨™è¨˜ç‰©ä»¥ç¯©é¸å¯èƒ½ç²ç›Šçš„æ‚£è€…äºç¾¤

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Gemcitabine]({{ "/drugs/gemcitabine/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Hydroxyprogesterone Caproate]({{ "/drugs/hydroxyprogesterone_caproate/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Dronedarone]({{ "/drugs/dronedarone/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Omalizumab]({{ "/drugs/omalizumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Oteracil]({{ "/drugs/oteracil/" | relative_url }}) - è­‰æ“šç­‰ç´š L2

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Regorafenibè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/regorafenib/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_regorafenib,
  title = {Regorafenibè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/regorafenib/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
